Figure 5 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Antitumor activity in mice inoculated with TROP2 3+ xenograft tumor models. A, PDX TROP2 3+ END(K)265 after one single retro-orbital injection with Dato-DXd compared with controls, including CTL-ADC, datopotamab, and control vehicle. A significant difference in tumor growth inhibition was detected beginning on day 8 (P < 0.05) in Dato-DXd–treated group when compared with the other control groups. B, OS of Dato-DXd was compared with the one of datopotamab, CTL-ADC, and control vehicle. The median survival for the Dato-DXd group was unreached, as all mice were alive, compared with 36 days for datopotamab, 32 days for CTL-ADC, and 29 days for control vehicle. C, Mouse weight change during the whole duration of treatment